Chinese oncology biotech behind sugemalimab (PD-L1 inhibitor), commercialized in China with Pfizer.
Chinese oncology biotech behind sugemalimab (PD-L1 inhibitor), commercialized in China with Pfizer.
In one line: A Chinese oncology biotech partnered with a US pharma major for distribution.
Moat: narrow (IP / patents, regulatory licence). Approved PD-L1 antibody with patent protection and a major-pharma distribution partner.
Headquarters: Suzhou, China · Founded: 2015 · Employees: 93
Size CStone Pharmaceuticals (2616.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.21B, the 531st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.89 on 18 Nov 2026.
Performance Over six months the shares fell 22.1%, against -17.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 116.7% over the last twelve months (peer median +5.9%); the operating margin is -88.7% (peer median 0.8%).
Valuation It trades at 17.0× enterprise value to sales against a peer median of 7.6× (3rd most expensive of 18).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$475M | HK$292M | HK$442M | HK$513M | HK$560M |
| Revenue growth | — | -34% | -14% | -8% | — |
| Gross profit | HK$218M | HK$7.88M | HK$206M | HK$315M | HK$299M |
| EBITDA | -HK$372M | -HK$403M | -HK$49.4M | -HK$605M | -HK$997M |
| Net income | -HK$470M | -HK$474M | -HK$98.9M | -HK$406M | -HK$1.05B |
| Free cash flow | -HK$315M | -HK$356M | -HK$335M | -HK$711M | -HK$833M |
| Capital expenditure | HK$0 | HK$0 | HK$0 | HK$71.9M | HK$118M |
| Total debt | n/a | HK$403M | HK$386M | HK$400M | HK$321M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| CStone Pharmaceuticals 2616.HK | $1.21B | -22% | +117% | -89% | 17.0× | n/a |
| Shanghai Junshi Biosciences 1877.HK | $3.49B | -38% | +36% | -14% | 8.4× | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | 12.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2616.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.9% | -5.4% | 2nd highest of 21 |
| 6-month return | -22.1% | -17.3% | 10th lowest of 21 |
| Distance from 52-week high | -43.4% | -39.3% | 9th lowest of 21 |
| Revenue growth (TTM) | +116.7% | +5.9% | 2nd highest of 18 |
| Operating margin | -88.7% | 0.8% | 5th lowest of 18 |
| EV / Sales | 17.0× | 7.6× | 3rd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | 13.6× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |